Proteostasis Therapeutics Stock Price, News & Analysis (NASDAQ:PTI)

$4.25 -0.03 (-0.70 %)
(As of 01/19/2018 01:52 PM ET)
Previous Close$4.28
Today's Range$4.24 - $4.53
52-Week Range$1.41 - $16.67
Volume673,200 shs
Average Volume749,175 shs
Market Capitalization$141.72 million
P/E Ratio-1.91
Dividend YieldN/A
Beta9.36

About Proteostasis Therapeutics (NASDAQ:PTI)

Proteostasis Therapeutics logoProteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.

Receive PTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTI
CUSIPN/A
Phone617-225-0096

Debt

Debt-to-Equity RatioN/A
Current Ratio4.21%
Quick Ratio4.21%

Price-To-Earnings

Trailing P/E Ratio-1.91440579096491
Forward P/E Ratio-1.72
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.38 million
Price / Sales16.79
Cash FlowN/A
Price / CashN/A
Book Value$3.26 per share
Price / Book1.30

Profitability

Trailing EPS($2.22)
Net Income$-37,230,000.00
Net Margins-712.49%
Return on Equity-93.15%
Return on Assets-76.61%

Miscellaneous

Employees73
Outstanding Shares33,110,000

Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions

What is Proteostasis Therapeutics' stock symbol?

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

How were Proteostasis Therapeutics' earnings last quarter?

Proteostasis Therapeutics Inc (NASDAQ:PTI) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.56) EPS for the quarter, topping the Zacks' consensus estimate of ($0.72) by $0.16. The business earned $1.55 million during the quarter, compared to analysts' expectations of $1.38 million. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%. View Proteostasis Therapeutics' Earnings History.

Where is Proteostasis Therapeutics' stock going? Where will Proteostasis Therapeutics' stock price be in 2018?

3 brokers have issued 12 month target prices for Proteostasis Therapeutics' shares. Their forecasts range from $8.00 to $25.00. On average, they expect Proteostasis Therapeutics' share price to reach $16.00 in the next twelve months. View Analyst Ratings for Proteostasis Therapeutics.

Are investors shorting Proteostasis Therapeutics?

Proteostasis Therapeutics saw a decrease in short interest in December. As of December 29th, there was short interest totalling 919,447 shares, a decrease of 52.3% from the December 15th total of 1,927,302 shares. Based on an average trading volume of 1,134,827 shares, the days-to-cover ratio is currently 0.8 days. Approximately 4.2% of the company's shares are sold short.

Who are some of Proteostasis Therapeutics' key competitors?

Who are Proteostasis Therapeutics' key executives?

Proteostasis Therapeutics' management team includes the folowing people:

  • M. James Barrett Ph.D., Independent Chairman of the Board (Age 74)
  • Meenu Chhabra, President, Chief Executive Officer, Director (Age 44)
  • Helen M. Boudreau, Chief Financial Officer, Principal Accounting Officer, Treasurer (Age 51)
  • Po-Shun Lee M.D., Executive Vice President, Chief Medical Officer (Age 47)
  • Benito Munoz, Chief Scientific Officer (Age 55)
  • Janet L. Smart, Vice President - Intellectual Property & Legal Affaris
  • Geoffrey S. Gilmartin M.D., Chief Development Officer (Age 49)
  • Franklin M. Berger, Independent Director (Age 67)
  • Jeffery W. Kelly Ph.D., Independent Director (Age 56)
  • Eric B Rabinowitz, Independent Director (Age 41)

When did Proteostasis Therapeutics IPO?

(PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

How do I buy Proteostasis Therapeutics stock?

Shares of Proteostasis Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Proteostasis Therapeutics' stock price today?

One share of Proteostasis Therapeutics stock can currently be purchased for approximately $4.25.

How big of a company is Proteostasis Therapeutics?

Proteostasis Therapeutics has a market capitalization of $141.72 million and generates $8.38 million in revenue each year. The company earns $-37,230,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Proteostasis Therapeutics employs 73 workers across the globe.

How can I contact Proteostasis Therapeutics?

Proteostasis Therapeutics' mailing address is 200 TECHNOLOGY SQUARE 4th FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-225-0096 or via email at [email protected]


MarketBeat Community Rating for Proteostasis Therapeutics (PTI)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  127 (Vote Underperform)
Total Votes:  214
MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Proteostasis Therapeutics (NASDAQ:PTI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$16.00$12.33$16.00
Price Target Upside: 257.94% upside257.94% upside450.60% upside280.05% upside

Proteostasis Therapeutics (NASDAQ:PTI) Consensus Price Target History

Price Target History for Proteostasis Therapeutics (NASDAQ:PTI)

Proteostasis Therapeutics (NASDAQ:PTI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/19/2017HC WainwrightReiterated RatingBuy$15.00LowView Rating Details
12/12/2017Leerink SwannBoost Price Target$6.00 -> $8.00HighView Rating Details
12/12/2017Robert W. BairdBoost Price TargetOutperform$13.00 -> $25.00HighView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
3/7/2016Royal Bank of CanadaInitiated CoverageOutperform$20.00N/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

Proteostasis Therapeutics (NASDAQ:PTI) Earnings History and Estimates Chart

Earnings by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Proteostasis Therapeutics (NASDAQ PTI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.72)($0.56)$1.38 million$1.55 millionViewN/AView Earnings Details
8/4/2017Q2 2017($0.61)($0.68)ViewN/AView Earnings Details
5/12/2017Q1 2017($0.58)($0.60)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.51)($0.38)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.50)($0.54)ViewN/AView Earnings Details
8/15/2016Q2 2016($0.41)($0.47)ViewN/AView Earnings Details
5/13/2016Q2($0.41)($0.47)$2.44 million$1.16 millionViewN/AView Earnings Details
9/5/2013Q3 13$0.03ViewN/AView Earnings Details
7/25/2011$0.11$0.29ViewN/AView Earnings Details
4/27/2011$0.39$0.40ViewN/AView Earnings Details
2/9/2011$0.37$0.49ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Proteostasis Therapeutics (NASDAQ:PTI) Earnings Estimates

2018 EPS Consensus Estimate: ($1.90)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.49)($0.49)($0.49)
Q2 20181($0.48)($0.48)($0.48)
Q3 20181($0.46)($0.46)($0.46)
Q4 20181($0.47)($0.47)($0.47)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Proteostasis Therapeutics (NASDAQ:PTI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Proteostasis Therapeutics (NASDAQ PTI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 51.80%
Insider Trades by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)
Institutional Ownership by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Proteostasis Therapeutics (NASDAQ PTI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2017Enterprise Associates 12 NewMajor ShareholderBuy2,000,000$5.00$10,000,000.00View SEC Filing  
12/18/2017Franklin M BergerDirectorBuy60,000$5.00$300,000.00266,162View SEC Filing  
12/18/2017Meenu ChhabraInsiderBuy40,000$5.00$200,000.0050,218View SEC Filing  
12/14/2017Cormorant Asset Management, LlMajor ShareholderSell504,027$4.88$2,459,651.76View SEC Filing  
3/13/2017Fmr LlcInsiderSell25,000$12.94$323,500.00View SEC Filing  
3/10/2017Fmr LlcInsiderSell25,000$12.04$301,000.00View SEC Filing  
3/9/2017Fmr LlcInsiderSell29,300$12.08$353,944.00View SEC Filing  
3/7/2017Fmr LlcInsiderSell60,000$13.01$780,600.00View SEC Filing  
3/3/2017Fmr LlcInsiderSell45,000$13.91$625,950.00View SEC Filing  
3/1/2017Fmr LlcInsiderSell45,000$14.62$657,900.00View SEC Filing  
2/27/2017Fmr LlcInsiderSell28,000$14.60$408,800.00View SEC Filing  
12/16/2016Franklin M BergerDirectorBuy40,000$11.17$446,800.00192,162View SEC Filing  
12/13/2016Cormorant Asset Management, LlMajor ShareholderBuy121,301$10.82$1,312,476.82View SEC Filing  
12/8/2016Cormorant Asset Management, LlMajor ShareholderBuy44,417$10.83$481,036.11View SEC Filing  
12/6/2016Cormorant Asset Management, LlMajor ShareholderBuy87,973$10.62$934,273.26View SEC Filing  
12/1/2016Cormorant Asset Management, LlMajor ShareholderBuy170,391$10.24$1,744,803.84View SEC Filing  
11/23/2016Cormorant Asset Management, LlMajor ShareholderBuy361,863$11.40$4,125,238.20View SEC Filing  
11/14/2016Cormorant Asset Management, LlMajor ShareholderBuy259,500$11.05$2,867,475.00View SEC Filing  
11/7/2016Cormorant Asset Management, LlMajor ShareholderBuy327,977$8.45$2,771,405.65View SEC Filing  
9/14/2016Enterprise Associates 12 NewMajor ShareholderBuy461,538$13.00$5,999,994.00View SEC Filing  
9/14/2016Franklin M BergerDirectorBuy69,230$13.00$899,990.00166,162View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
2/17/2016Franklin M. BergerDirectorBuy25,000$8.00$200,000.0096,932View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Proteostasis Therapeutics (NASDAQ PTI) News Headlines

Source:
DateHeadline
Proteostasis Therapeutics (PTI) Rating Lowered to Sell at Zacks Investment ResearchProteostasis Therapeutics (PTI) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 18 at 12:10 PM
Apartments, condos planned near Boston Landing MBTA stop - Boston Business JournalApartments, condos planned near Boston Landing MBTA stop - Boston Business Journal
www.bizjournals.com - January 18 at 11:11 AM
Proteostasis Therapeutics Inc (PTI) Short Interest Down 52.3% in DecemberProteostasis Therapeutics Inc (PTI) Short Interest Down 52.3% in December
www.americanbankingnews.com - January 14 at 4:10 AM
Proteostasis Therapeutics Inc (PTI) Expected to Post Quarterly Sales of $1.58 MillionProteostasis Therapeutics Inc (PTI) Expected to Post Quarterly Sales of $1.58 Million
www.americanbankingnews.com - January 11 at 12:02 PM
Proteostasis’ Proprietary Triple Combination Therapy Study Protocol Receives Endorsement and High Strategic Fit Score from the Largest Cystic Fibrosis Patient Advocacy Groups in the U.S. and EuropeProteostasis’ Proprietary Triple Combination Therapy Study Protocol Receives Endorsement and High Strategic Fit Score from the Largest Cystic Fibrosis Patient Advocacy Groups in the U.S. and Europe
finance.yahoo.com - January 8 at 10:23 AM
Proteostasis Therapeutics (PTI) Downgraded by ValuEngine to "Strong Sell"Proteostasis Therapeutics (PTI) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - January 1 at 12:52 PM
Short Interest in Proteostasis Therapeutics Inc (PTI) Rises By 288.9%Short Interest in Proteostasis Therapeutics Inc (PTI) Rises By 288.9%
www.americanbankingnews.com - December 30 at 2:00 AM
Proteostasis Therapeutics (PTI) versus The Competition Financial AnalysisProteostasis Therapeutics (PTI) versus The Competition Financial Analysis
www.americanbankingnews.com - December 29 at 3:28 AM
ETFs with exposure to Proteostasis Therapeutics, Inc. : December 26, 2017ETFs with exposure to Proteostasis Therapeutics, Inc. : December 26, 2017
finance.yahoo.com - December 27 at 2:33 PM
Proteostasis Therapeutics Inc (PTI) Expected to Announce Quarterly Sales of $1.59 MillionProteostasis Therapeutics Inc (PTI) Expected to Announce Quarterly Sales of $1.59 Million
www.americanbankingnews.com - December 25 at 4:46 AM
Proteostasis Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesProteostasis Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - December 22 at 10:22 AM
Proteostasis Therapeutics (PTI) Stock Rating Reaffirmed by HC WainwrightProteostasis Therapeutics (PTI) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - December 19 at 1:18 PM
Proteostasis Therapeutics Inc (PTI) Director Franklin M. Berger Acquires 60,000 SharesProteostasis Therapeutics Inc (PTI) Director Franklin M. Berger Acquires 60,000 Shares
www.americanbankingnews.com - December 19 at 11:30 AM
Meenu Chhabra Buys 40,000 Shares of Proteostasis Therapeutics Inc (PTI) StockMeenu Chhabra Buys 40,000 Shares of Proteostasis Therapeutics Inc (PTI) Stock
www.americanbankingnews.com - December 19 at 11:28 AM
Insider Buying: Proteostasis Therapeutics Inc (PTI) Major Shareholder Acquires 2,000,000 Shares of StockInsider Buying: Proteostasis Therapeutics Inc (PTI) Major Shareholder Acquires 2,000,000 Shares of Stock
www.americanbankingnews.com - December 19 at 11:28 AM
Proteostasis Therapeutics Inc (PTI) President and CEO Meenu Chhabra Bought $200,000 of SharesProteostasis Therapeutics Inc (PTI) President and CEO Meenu Chhabra Bought $200,000 of Shares
finance.yahoo.com - December 19 at 10:18 AM
Head to Head Survey: Proteostasis Therapeutics (PTI) and Its PeersHead to Head Survey: Proteostasis Therapeutics (PTI) and Its Peers
www.americanbankingnews.com - December 18 at 9:22 PM
Insider Selling: Proteostasis Therapeutics Inc (PTI) Major Shareholder Sells 504,027 Shares of StockInsider Selling: Proteostasis Therapeutics Inc (PTI) Major Shareholder Sells 504,027 Shares of Stock
www.americanbankingnews.com - December 18 at 8:36 PM
Proteostasis Therapeutics Inc Expected to Earn Q1 2018 Earnings of ($0.49) Per Share (PTI)Proteostasis Therapeutics Inc Expected to Earn Q1 2018 Earnings of ($0.49) Per Share (PTI)
www.americanbankingnews.com - December 14 at 11:04 AM
Proteostasis Therapeutics (PTI) Reports Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808Proteostasis Therapeutics (PTI) Reports Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808
www.streetinsider.com - December 13 at 4:49 PM
Proteostasis Soars on News of Positive Trial Results, Baird Says OutperformProteostasis Soars on News of Positive Trial Results, Baird Says Outperform
finance.yahoo.com - December 13 at 10:35 AM
Proteostasis Stock Surges on Positive Data From CF StudiesProteostasis Stock Surges on Positive Data From CF Studies
finance.yahoo.com - December 13 at 10:35 AM
Proteostasis Therapeutics Inc (PTI) Is Blasting Off 165% Following Three Clinical Wins in Cystic FibrosisProteostasis Therapeutics Inc (PTI) Is Blasting Off 165% Following Three Clinical Wins in Cystic Fibrosis
finance.yahoo.com - December 12 at 5:00 PM
Proteostasis Therapeutics shares down 8% after proposed share offeringProteostasis Therapeutics shares down 8% after proposed share offering
finance.yahoo.com - December 12 at 5:00 PM
ETFs with exposure to Proteostasis Therapeutics, Inc. : December 12, 2017ETFs with exposure to Proteostasis Therapeutics, Inc. : December 12, 2017
finance.yahoo.com - December 12 at 5:00 PM
Proteostasis Therapeutics (PTI) Price Target Increased to $8.00 by Analysts at Leerink SwannProteostasis Therapeutics (PTI) Price Target Increased to $8.00 by Analysts at Leerink Swann
www.americanbankingnews.com - December 12 at 3:16 PM
Proteostasis Therapeutics stock nearly doubles on heavy volume after positive trial resultsProteostasis Therapeutics' stock nearly doubles on heavy volume after positive trial results
finance.yahoo.com - December 12 at 10:42 AM
Proteostasis Therapeutics (PTI) Given New $25.00 Price Target at Robert W. BairdProteostasis Therapeutics (PTI) Given New $25.00 Price Target at Robert W. Baird
www.americanbankingnews.com - December 12 at 8:52 AM
30 Stocks Moving In Tuesdays Pre-Market Session30 Stocks Moving In Tuesday's Pre-Market Session
feeds.benzinga.com - December 12 at 8:41 AM
Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 andProteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and
www.nasdaq.com - December 11 at 4:49 PM
Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and Patients with Cystic FibrosisProteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis
finance.yahoo.com - December 11 at 4:49 PM
Contrasting Proteostasis Therapeutics (PTI) & The CompetitionContrasting Proteostasis Therapeutics (PTI) & The Competition
www.americanbankingnews.com - December 10 at 12:14 PM
-$0.65 Earnings Per Share Expected for Proteostasis Therapeutics Inc (PTI) This Quarter-$0.65 Earnings Per Share Expected for Proteostasis Therapeutics Inc (PTI) This Quarter
www.americanbankingnews.com - December 6 at 3:12 AM
FY2018 EPS Estimates for Proteostasis Therapeutics Inc (PTI) Lifted by Leerink SwannFY2018 EPS Estimates for Proteostasis Therapeutics Inc (PTI) Lifted by Leerink Swann
www.americanbankingnews.com - December 4 at 7:28 AM
Proteostasis Therapeutics, Inc. :PTI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Proteostasis Therapeutics, Inc. :PTI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:20 AM
Zacks Investment Research Downgrades Proteostasis Therapeutics, Inc. (PTI) to SellZacks Investment Research Downgrades Proteostasis Therapeutics, Inc. (PTI) to Sell
www.americanbankingnews.com - November 18 at 6:04 AM
Proteostasis Therapeutics, Inc. (PTI) Releases Quarterly  Earnings Results, Beats Estimates By $0.16 EPSProteostasis Therapeutics, Inc. (PTI) Releases Quarterly Earnings Results, Beats Estimates By $0.16 EPS
www.americanbankingnews.com - November 15 at 1:01 PM
Proteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio UpdateProteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update
finance.yahoo.com - November 15 at 7:42 AM
Analyzing Xencor (XNCR) & Proteostasis Therapeutics (PTI)Analyzing Xencor (XNCR) & Proteostasis Therapeutics (PTI)
www.americanbankingnews.com - November 15 at 5:28 AM
ETFs with exposure to Proteostasis Therapeutics, Inc. : November 6, 2017ETFs with exposure to Proteostasis Therapeutics, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 9:10 AM
Proteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration ProgramsProteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Programs
finance.yahoo.com - November 1 at 7:44 AM
$1.38 Million in Sales Expected for Proteostasis Therapeutics, Inc. (PTI) This Quarter$1.38 Million in Sales Expected for Proteostasis Therapeutics, Inc. (PTI) This Quarter
www.americanbankingnews.com - October 30 at 4:02 AM
ETFs with exposure to Proteostasis Therapeutics, Inc. : October 26, 2017ETFs with exposure to Proteostasis Therapeutics, Inc. : October 26, 2017
finance.yahoo.com - October 27 at 11:57 AM
ETFs with exposure to Proteostasis Therapeutics, Inc. : October 16, 2017ETFs with exposure to Proteostasis Therapeutics, Inc. : October 16, 2017
finance.yahoo.com - October 17 at 6:30 AM
Is Proteostasis Therapeutics Inc (PTI) Thriving Or Barely Surviving In The Healthcare Sector?Is Proteostasis Therapeutics Inc (PTI) Thriving Or Barely Surviving In The Healthcare Sector?
finance.yahoo.com - October 12 at 8:38 AM
Is Proteostasis Therapeutics Inc (PTI) Thriving Or Barely Surviving In The Healthcare Sector?Is Proteostasis Therapeutics Inc (PTI) Thriving Or Barely Surviving In The Healthcare Sector?
finance.yahoo.com - October 12 at 8:38 AM
Proteostasis Therapeutics, Inc. (PTI) Expected to Post Quarterly Sales of $1.38 MillionProteostasis Therapeutics, Inc. (PTI) Expected to Post Quarterly Sales of $1.38 Million
www.americanbankingnews.com - October 11 at 7:36 AM
-$0.63 Earnings Per Share Expected for Proteostasis Therapeutics, Inc. (PTI) This Quarter-$0.63 Earnings Per Share Expected for Proteostasis Therapeutics, Inc. (PTI) This Quarter
www.americanbankingnews.com - October 9 at 12:38 PM
Proteostasis Therapeutics, Inc. (PTI) Expected to Announce Earnings of -$0.63 Per ShareProteostasis Therapeutics, Inc. (PTI) Expected to Announce Earnings of -$0.63 Per Share
www.americanbankingnews.com - September 21 at 12:20 AM
ETFs with exposure to Proteostasis Therapeutics, Inc. : September 1, 2017ETFs with exposure to Proteostasis Therapeutics, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 7:37 AM

SEC Filings

Proteostasis Therapeutics (NASDAQ:PTI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Proteostasis Therapeutics (NASDAQ:PTI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Proteostasis Therapeutics (NASDAQ PTI) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.